Core Insights - Agilent Technologies reported revenue of $1.67 billion for the quarter ended April 2025, reflecting a 6% increase year-over-year and exceeding the Zacks Consensus Estimate of $1.63 billion by 2.64% [1] - The company's EPS for the quarter was $1.31, up from $1.22 in the same quarter last year, surpassing the consensus estimate of $1.26 by 3.97% [1] Revenue Performance by End Markets - Pharmaceutical revenue reached $603 million, exceeding the average estimate of $572.63 million, with a year-over-year increase of 11.3% [4] - Academia and Government revenue was $135 million, below the average estimate of $145.13 million, representing a decline of 2.9% year-over-year [4] - Diagnostics and Clinical revenue amounted to $255 million, surpassing the average estimate of $247.93 million, with a year-over-year increase of 6.7% [4] - Agilent Crosslab Group net revenue was $713 million, exceeding the estimated $697.53 million, showing a significant year-over-year increase of 77.4% [4] - Food revenue was reported at $147 million, slightly above the average estimate of $146.05 million, with a year-over-year increase of 5.8% [4] - Environmental and Forensics revenue was $159 million, in line with the average estimate of $159.54 million, reflecting a year-over-year increase of 4.6% [4] - Chemical and advanced materials revenue was $369 million, slightly below the average estimate of $370.20 million, with a year-over-year increase of 1.9% [4] Stock Performance - Agilent's shares have returned +3.5% over the past month, compared to a +7.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

分组1 - Agilent Technologies reported quarterly earnings of $1.31 per share, exceeding the Zacks Consensus Estimate of $1.26 per share, and showing an increase from $1.22 per share a year ago, representing an earnings surprise of 3.97% [1] - The company achieved revenues of $1.67 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.64% and increasing from $1.57 billion year-over-year [2] - Agilent has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - Despite the positive earnings report, Agilent shares have declined approximately 17.2% since the beginning of the year, contrasting with the S&P 500's gain of 0.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $1.40 on revenues of $1.65 billion, and for the current fiscal year, it is $5.54 on revenues of $6.73 billion [7] 分组3 - The Zacks Industry Rank indicates that the Medical - Products industry is currently in the bottom 44% of over 250 Zacks industries, which may negatively impact Agilent's stock performance [8] - The estimate revisions trend for Agilent is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $1.67 billion, representing a 6% reported growth and a 5.3% core growth compared to Q2 2024 [9][27] - Operating margin was 25.1%, absorbing some incremental tariff costs, and EPS was $1.31, growing 7% year over year [9][33] - Gross margin was 54.1%, down from the previous year due to tariffs, currency, and product mix [31] Business Line Data and Key Metrics Changes - The Agilent CrossLab Group reported revenue of $713 million, growing 9%, driven by double-digit growth in consumables and automation [28] - Life Sciences and Diagnostics Market Group revenue was $654 million, growing 3%, with high single-digit growth in pathology and NASD [29] - Applied Markets Group revenue was flat at $300 million, with growth in spectroscopy offset by declines in gas chromatography [29] Market Data and Key Metrics Changes - All regions experienced growth, with China leading at 10%, while the Americas grew low single digits and EMEA grew mid single digits [12] - India delivered high teens growth, prompting the opening of a new solution center [13] - PFAS testing grew over 70% year over year globally, with Europe and China more than doubling their business [15][16] Company Strategy and Development Direction - The company is executing its three-year Ignite transformation strategy, focusing on operational efficiency and tariff mitigation [11][20] - Agilent acquired BioVectra for approximately $1 billion to expand its CDMO capabilities [20] - The company is committed to innovation, launching new products in cell analysis and chromatography [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth prospects despite macroeconomic uncertainties, maintaining a core growth rate of 2.5% to 3.5% for the year [26][37] - The company is proactively managing tariff exposure and expects to fully mitigate costs by fiscal 2026 [25][39] - Management highlighted the importance of strategic pricing initiatives to maintain competitiveness [21][84] Other Important Information - Digital orders grew by 12% year over year, reaching $295 million [18] - The company is tracking over 350 regulations globally related to PFAS testing, anticipating significant market growth [16][22] - The board welcomed new members with extensive experience in the pharmaceutical and healthcare sectors [42] Q&A Session Summary Question: Order trends in the quarter - Management noted that orders grew low single digits in Q2, with a book-to-bill ratio greater than one, indicating stable business across regions [49][50] Question: Performance of NASD and BioVectra - Management expressed optimism about the CDMO business, with expectations for double-digit growth in the second half of the year [55] Question: Impact of tariffs on consumables - The $15 million of consumables pulled forward was due to customer anticipation of tariffs, with no overall revenue impact expected [63][64] Question: Differences in ordering patterns in pharma - The majority of business is in QAQC and development, with small molecule growth of 10% in the quarter [71] Question: PFAS regulation impacts - PFAS testing grew 75% year over year, with expectations for continued strong results despite regulatory uncertainties [73][75] Question: Reshoring and capacity build-outs - Discussions with pharma customers are early, with expectations for potential tailwinds in the next few years [82] Question: Pricing strategies - The company is on track for approximately 100 basis points of price realization for the year, aided by tariff mitigation activities [86][88]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $1.67 billion, representing a 6% increase reported and 5.3% core growth year-over-year [9][27] - Operating margin was 25.1%, absorbing some incremental tariff costs, and EPS was $1.31, growing 7% compared to Q2 2024 [9][33] - Gross margin was 54.1%, down from the previous year due to tariffs, currency, and product mix [31] Business Line Data and Key Metrics Changes - The Agilent CrossLab Group reported revenue of $713 million, growing 9%, driven by double-digit growth in consumables and automation [28] - Life Sciences and Diagnostics Market Group revenue was $654 million, growing 3%, with high single-digit growth in pathology and NASD [29] - Applied Markets Group revenue was flat at $300 million, with growth in spectroscopy offset by declines in gas chromatography [29] Market Data and Key Metrics Changes - All regions experienced growth: Americas grew low single digits, EMEA grew mid single digits, and China led with 10% growth [12] - India delivered high teens growth, prompting the opening of a new solution center [13] - Environmental and forensics grew 6% globally, driven by strong demand for PFAS testing [15] Company Strategy and Development Direction - The company is executing its three-year Ignite transformation strategy, focusing on operational efficiency and tariff mitigation [11][20] - Agilent acquired BioVectra for approximately $1 billion to expand CDMO capabilities [20] - The company is committed to innovation, launching new products in cell analysis and chromatography [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth prospects despite macroeconomic uncertainties [26] - The company is maintaining its core growth rate guidance of 2.5% to 3.5% for the year [26][35] - Management highlighted the importance of strategic pricing initiatives to mitigate tariff impacts [21][88] Other Important Information - The company is tracking over 350 regulations globally related to PFAS testing, anticipating significant market growth by 2030 [16] - Operating cash flow was $221 million, with capital expenditures of $114 million [33] - The company ended the quarter with a net leverage ratio of 1, indicating a strong balance sheet [33] Q&A Session Summary Question: Order trends in the quarter - Management noted that orders grew low single digits in Q2, with stable business across regions and no significant pull forward from pharma tariffs [50][51] Question: Expectations for NASD and BioVectra - Management expressed confidence in double-digit growth for NASD in the second half of the year, supported by strong order visibility [56] Question: Impact of tariffs on consumables - The $15 million pull forward in consumables was driven by customer actions in response to high tariff rates, with no overall revenue impact expected [64][65] Question: Differences in ordering patterns in pharma - The majority of business is on the QAQC and development side, with small molecule growth of 10% in the quarter [72] Question: PFAS regulation impacts - PFAS testing grew 75% year-over-year, with expectations for continued strong results despite regulatory uncertainties [74] Question: Reshoring and capacity build-outs - Discussions with pharma customers regarding reshoring are still in early stages, with potential tailwinds expected in the next 2-3 years [84] Question: Pricing strategies - The company has established enterprise pricing capabilities and is on track for approximately 100 basis points of price realization for the year [88][90]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $1,670 million, representing a 6% reported growth and a 5.3% core growth compared to Q2 2024 [6][26] - Operating margin was 25.1%, and EPS was $1.31, growing 7% year over year [6][32] - The company experienced its fourth consecutive quarter of accelerating growth [7] Business Line Data and Key Metrics Changes - The Agilent CrossLab Group reported revenue of $713 million, growing 9% [27] - Life Sciences and Diagnostics Market Group revenue was $654 million, growing 3% [28] - Applied Markets Group revenue was flat at $300 million on a core growth basis [28] Market Data and Key Metrics Changes - All regions experienced growth: Americas grew low single digits, EMEA grew mid single digits, and China led with 10% growth [9][11] - India delivered high teens growth, and the company opened its first solution center in India [11] - PFAS testing grew more than 70% year over year globally, with Europe and China more than doubling their business [13][14] Company Strategy and Development Direction - The company is executing its three-year Ignite transformation strategy, which has resulted in early wins and tariff mitigation [8][20] - Agilent is focused on innovation and has launched several new products, including the Seahorse XF Flex analyzer and the InfinityLab Pro IQ series [22][23] - The company is committed to maintaining a strong balance sheet and exploring external growth opportunities [41] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about long-term growth prospects, maintaining a core growth rate of 2.5% to 3.5% for the year [25][36] - The company is proactively managing tariff exposure and expects to fully mitigate costs by fiscal 2026 [24][37] - Despite exceeding expectations in Q2, management emphasizes the importance of a disciplined outlook due to ongoing macroeconomic uncertainties [26] Other Important Information - The company has a robust pipeline of opportunities aligned with its strategy and is focused on augmenting internal innovation with external growth [41] - Agilent's digital orders grew by 12% year over year to $295 million [16] Q&A Session Summary Question: Can you provide insights on order trends during the quarter? - Orders grew low single digits in Q2, with stable business across regions and no significant pull forward from pharma tariffs [47][48] Question: What are the expectations for the NASD and BioVectra businesses? - The CDMO business is seeing high single-digit growth, with confidence in double-digit growth for the second half of the year [50][53] Question: What was the impact of tariffs on consumables? - The $15 million of consumables pulled forward was due to customer anticipation of tariffs, with no overall revenue impact for Q2 [60][61] Question: How is the Infinity Tree replacement cycle performing? - The Infinity Tree ramp is strong, with positive customer feedback and increasing adoption rates [88][89] Question: What is the outlook for pricing in light of tariffs? - The company has achieved significant pricing contributions and expects to maintain pricing strategies to mitigate tariff impacts [83][85]

FINANCIAL RESULTS OVERVIEW Q2 FY2025 May 28, 2025 Thank You for Your Attention Safe Harbor (1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX. (2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website. 03 This presentation contains forward- looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operat ...

Financial Performance - Agilent reported revenue of $1.67 billion for Q2 FY 2025, representing a growth of 6.0% reported and 5.3% core compared to Q2 FY 2024[3]. - GAAP net income for Q2 FY 2025 was $215 million, or $0.75 per share, down 29% from $308 million, or $1.05 per share in Q2 FY 2024[4]. - Non-GAAP net income for Q2 FY 2025 was $373 million, or $1.31 per share, up 7% from $356 million, or $1.22 per share in the same quarter last year[4]. - The full-year revenue outlook for FY 2025 is projected to be between $6.73 billion and $6.81 billion, indicating a growth of 3.4% to 4.6% reported[4]. - Q3 FY 2025 revenue outlook is expected to be in the range of $1.645 billion to $1.675 billion, representing an increase of 4.2% to 6.1% reported[4]. - Net income for the six months ended April 30, 2025, was $533 million, a decrease of 18.8% compared to $656 million for the same period in 2024[21]. - Non-GAAP net income for the six months ended April 30, 2025, was $750 million, representing an increase of 1.9% from $736 million in 2024[22]. Segment Performance - The Life Sciences and Diagnostics Markets Group reported Q2 revenue of $654 million, an increase of 8% reported and 3% core year-over-year[6]. - The Agilent CrossLab Group reported Q2 revenue of $713 million, an increase of 7% reported and 9% core year-over-year[6]. - The Applied Markets Group reported Q2 revenue of $301 million, a decrease of 1% reported and flat core year-over-year[7]. - Revenue for the Life Sciences and Diagnostics Markets Segment increased by 8% year-over-year, reaching $654 million in Q2 2025 compared to $604 million in Q2 2024[40]. - Revenue for the Agilent CrossLab Segment grew by 7% year-over-year, totaling $713 million in Q2 2025, up from $664 million in Q2 2024[40]. - The Applied Markets Segment reported a slight decline in revenue of 1%, with $301 million in Q2 2025 compared to $305 million in Q2 2024[40]. Cash Flow and Expenditures - Cash flows from operating activities for the six months ended April 30, 2025, were $652 million, down from $818 million in the same period of 2024[21]. - The company incurred $211 million in capital expenditures for property, plant, and equipment during the six months ended April 30, 2025, compared to $193 million in 2024[21]. - The net cash used in financing activities was $296 million for the six months ended April 30, 2025, a decrease from $531 million in 2024[21]. - The company reported a net cash increase of $157 million for the six months ended April 30, 2025, compared to an increase of $81 million in the same period of 2024[21]. Operational Insights - The gross margin for the Life Sciences and Diagnostics Markets Segment was 52.8% in Q2 2025, down from 55.1% in Q2 2024[35]. - Agilent's Ignite Transformation is driving financial success and operational excellence, becoming the core enterprise delivery engine[5]. Earnings Per Share - Non-GAAP EPS for Q3 FY 2025 is expected to be in the range of $1.35 to $1.37 per share[4].

Core Viewpoint - The article highlights various high-paying job opportunities in the scientific instrument sector, emphasizing the demand for skilled professionals in sales and technical support roles across different companies [2][17]. Job Opportunities - Agilent Technologies (China) is hiring for a complete machine sales position in Chongqing with a salary range of 10k to 20k and a 13th-month salary [2]. - Changzhou Panno Instrument Co., Ltd. is looking for a gas chromatography and mass spectrometry sales position in Chongqing, offering a salary of 8k to 12k with a 13th-month salary [4]. - Labtech is seeking a sales engineer in Guizhou with a salary range of 8k to 12k and a 12th-month salary [6]. - Shanghai Flash Spectrum Biotechnology Co., Ltd. is hiring for an analytical liquid chromatography sales engineer in Hangzhou, with a salary range of 20k to 30k and a 12th-month salary [8]. - Scikam (Beijing) Scientific Instrument Co., Ltd. is looking for a regional sales manager in Hangzhou, offering a negotiable salary [10]. Job Requirements - Candidates for Agilent Technologies should have a background in chemistry, pharmacy, biology, food, environment, or materials, with at least 2 years of relevant sales/application/support experience [3]. - For the gas chromatography and mass spectrometry sales position at Changzhou Panno, a background in analytical chemistry, chemical engineering, inspection and quarantine, or related fields is preferred [4]. - The sales engineer position at Labtech requires a degree in analytical chemistry, applied chemistry, food, agriculture, or environmental science, along with some sales experience [6]. - The regional sales manager role at Scikam requires familiarity with chromatography instruments and at least 2 years of sales experience in the instrument industry [10]. After-sales Positions - Hitachi Scientific Instruments (Beijing) Co., Ltd. is hiring an electron microscope application engineer in Chengdu, requiring a master's degree and over 3 years of relevant experience [18]. - Beijing Pulit Technology Co., Ltd. is looking for a service engineer in Hefei, with a salary range of 10k to 15k and a 12th-month salary, requiring a master's degree and strong electrical knowledge [20]. - Shanghai Linli Instrument Co., Ltd. is seeking an inorganic analysis after-sales engineer in Fuzhou, offering a salary range of 10k to 30k with a 13th-month salary, requiring 2 years of relevant experience [22].

Core Viewpoint - The procurement market for gas chromatography instruments in universities is characterized by a "domestic for teaching and imported for research" stratification, with domestic replacements accelerating in basic teaching but high-end research equipment still heavily reliant on imports [1][7][24]. Procurement Market Analysis - From 2024 to 2025, universities are expected to significantly increase the quantity of domestic gas chromatography instruments in their procurement, although the monetary share remains low. Research institutions and universities are the main purchasers, focusing on both research and teaching applications, with a total procurement of 139 units [1][3]. - In March 2025, universities accounted for 70.59% of the total procurement quantity of gas chromatography instruments, with a procurement amount of 341.21 million yuan, representing 46.74% of the total procurement amount for that month [3][19]. Pricing and Cost Analysis - Imported brands have unit prices ranging from 280,000 to 650,000 yuan, with high-end models exceeding 600,000 yuan. In contrast, domestic brands have basic teaching models priced between 50,000 and 200,000 yuan, and mid-range models priced between 100,000 and 300,000 yuan [2][11]. - By 2030, the share of domestic gas chromatography instruments in university procurement is expected to rise to 35%-40%, contingent upon overcoming core component technology barriers [2][24]. Brand Distribution and Domestic Progress - The procurement market shows a clear polarization, with imported brands dominating the research field while domestic brands are rapidly growing in teaching and routine research scenarios. In 2024, 47 brands were awarded contracts, with 37 being domestic and 9 imported [6][24]. - In January 2025, domestic brands accounted for 80.82% of the total number of awarded contracts, indicating a significant increase in market share due to policy support [8][21]. Procurement Strategy - Universities employ differentiated procurement strategies based on teaching and research scenarios. Teaching scenarios often use competitive negotiation to balance cost and performance, while research scenarios typically use public bidding to ensure quality [4][16]. - The procurement budget aligns closely with the scenario needs, with lower budgets for teaching experiments and higher budgets for research projects [4][12]. Regional Distribution - Guangdong, Inner Mongolia, and Sichuan are the top three regions for procurement project numbers, reflecting the correlation between regional research strength, educational investment, and industrial layout [5][19]. Future Market Trends - The market for gas chromatography instruments is expected to diversify, with domestic replacements accelerating but high-end markets requiring more time for complete substitution. The domestic market share is projected to grow from around 25% in 2024 to 35%-40% by 2030 [27][31]. - Technological upgrades will drive market development, with new high-sensitivity and high-resolution gas chromatography instruments becoming focal points for industry growth [28][33].

Core Viewpoint - Agilent Technologies is expected to report quarterly earnings of $1.27 per share, a 4.1% increase year-over-year, with revenues projected at $1.63 billion, reflecting a 3.3% increase compared to the same period last year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 0.1% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Estimates by End Markets - Revenue by End Markets- Diagnostics and Clinical is estimated at $247.93 million, a year-over-year increase of 3.7% [5]. - Revenue by End Markets- Chemical and Advanced Materials is projected to reach $370.20 million, reflecting a 2.3% increase from the previous year [5]. - Revenue by End Markets- Food is expected to be $146.05 million, indicating a 5.1% year-over-year change [5]. - Revenue by End Markets- Academia and Government is forecasted at $145.13 million, suggesting a 4.4% increase year-over-year [6]. - Net Revenue- Life Sciences and Applied Markets Group is anticipated to be $628.72 million, showing a significant decline of 16.6% year-over-year [6]. - Net Revenue- Agilent Crosslab Group is projected at $697.53 million, indicating a substantial increase of 73.5% year-over-year [6]. - Revenue by End Markets- Pharmaceutical is expected to reach $572.63 million, reflecting a 5.7% increase from the prior year [7]. - Revenue by End Markets- Environmental and Forensics is estimated at $159.54 million, indicating a 5% increase year-over-year [7]. Stock Performance - Over the past month, Agilent shares have returned 3.7%, compared to a 13.4% increase in the Zacks S&P 500 composite [7]. - Agilent currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [7].